Patient demographics at initial treatment
| Overall | Anti-VEGF monotherapy | Combination therapy | Unused therapy | P value | |
| Number of eyes | 2049 | 427 | 807 | 815 | – |
| Number of patients | 1552 | 292 | 617 | 643 | – |
| Mean age (years) | 63.5±10.8 | 65.0±10.9 | 62.6±11.2 | 63.6±10.1 | 0.003 |
| Sex, male/female | 989/563 | 193/99 | 393/224 | 403/240 | 0.601 |
| Duration of diabetes, (M) | 94 (36−168) | 85 (24−180) | 72 (24−144) | 120 (36−180) | 0.063 |
| HbA1c (%) | 7.7±1.8 | 7.7±1.7 | 7.7±1.9 | 7.7±1.7 | 0.998 |
| eGFR (mL/min/1.73 m2) | 64.8±27.2 | 66.1±28.2 | 66.6±27.3 | 62.4±26.6 | 0.102 |
| Cataract surgery | n=818 (39.9%) | n=120 (28.1%) | n=389 (48.2%) | n=309 (37.9%) | <0.001 |
| Peripheral photocoagulation | n=617 (30.1%) | n=72 (16.9%) | n=308 (38.2%) | n=237 (29.1%) | <0.001 |
eGFR, estimated glomerular filtration rate; HbA1c, glycohaemoglobin; VEGF, vascular endothelial growth factor.